{
  "id": "DSM-5_42881174",
  "corpus": "DSM-5",
  "condition": "General",
  "text": "252 Substance-Related and Addictive Disorders Unspecified Phencyclidine-Related Disorder 292.9 (F16.99) This category applies to presentations in which symptoms character- istic of a phencyclidine-related disorder that cause clinically signifi- cant distress or impairment in social, occupational, or other important areas of functioning predominate but do not meet the full criteria for any specific phencyclidine-related disorder or any of the disorders in the substance-related and addictive disorders diagnostic class. Unspecified Hallucinogen-Related Disorder 292.9 (F16.99) This category applies to presentations in which symptoms character- istic of a hallucinogen-related disorder that cause clinically significant distress or impairment in social, occupational, or other important ar- eas of functioning predominate but do not meet the full criteria for any specific hallucinogen-related disorder or any of the disorders in the substance-related and addictive disorders diagnostic class. Inhalant-Related Disorders Inhalant Use Disorder A. A problematic pattern of use of a hydrocarbon-based inhalant substance leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period: 1. The inhalant substance is often taken in larger amounts or over a longer period than was intended. Inhalant Use Disorder 253 2. There is a persistent desire or unsuccessful efforts to cut down or control use of the inhalant substance. 3. A great deal of time is spent in activities necessary to obtain the inhalant substance, use it, or recover from its effects. 4. Craving, or a strong desire or urge to use the inhalant sub- stance. 5. Recurrent use of the inhalant substance resulting in a failure to fulfill major role obligations at work, school, or home. 6. Continued use of the inhalant substance despite having per- sistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use. 7. Important social, occupational, or recreational activities are giv- en up or reduced because of use of the inhalant substance. 8. Recurrent use of the inhalant substance in situations in which it is physically hazardous. 9. Use of the inhalant substance is continued despite knowl- edge of having a persistent or recurrent physical or psy- chological problem that is likely to have been caused or exacerbated by the substance. 10. Tolerance, as defined by either of the following: a. A need for markedly increased amounts of the inhalant substance to achieve intoxication or desired effect. b. A markedly diminished effect with continued use of the same amount of the inhalant substance. Specify the particular inhalant: When possible, the particular sub- stance involved should be named (e.g., “solvent use disorder”). Specify if: In early remission: After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met). In sustained remission: After full criteria for inhalant use disor- der were previously met, none of the criteria for inhalant use dis- order have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met).",
  "reasoning_hint": {
    "has_risk": false,
    "has_action": false,
    "has_followup": false
  }
}